Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Fujimasa Tada; Atsushi Hiraoka; Hideko Ohama; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada

doi:10.1111/hepr.70190

April 21, 2026Hepatology Research

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the clinical characteristics, predictive factors, and effects of antithrombotic therapy on bleeding events in unresectable hepatocellular carcinoma patients treated with Atezolizumab and Bevacizumab.
Analyzed bleeding events during Atezolizumab and Bevacizumab therapy
Evaluated associations between bleeding events and tumor burden
Reviewed overall survival outcomes related to bleeding complications
Bleeding events were linked more to tumor burden than to antithrombotic therapy or portal hypertension
Patients with bleeding events exhibited poorer overall survival
Caution is advised in interpreting the relationship between bleeding and mortality as it may reflect tumor aggression rather than treatment effects

Implication

Observational study reveals antithrombotic therapy impacts bleeding events in hepatocellular carcinoma, indicating careful monitoring is essential.

Abstract

During Atez/Bev therapy, BL-AEs were primarily associated with advanced tumor burden rather than with ATT or baseline portal hypertension-related factors. Although BL-AEs were associated with poorer OS, this should be interpreted cautiously, as bleeding may reflect aggressive tumor biology rather than a direct mortality cause. Careful monitoring for bleeding complications may be required in patients with advanced tumor burden receiving Atez/Bev.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tada et al. (2026) studied this question.

synapsesocial.com/papers/69e9b7c585696592c86eb60e https://doi.org/10.1111/hepr.70190

View Full Paper

Ask AI

Bookmark

Share

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Key Points

Implication

Abstract

Discussion

Cite This Study

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading